INTRODUCTION: Migraine is a common and highly disabling neurological disorder 
whose acute treatment remains problematic and unsatisfactory in a high 
percentage of cases. Consequently, there remains a need for new symptomatic 
therapies that can be easily handled by patients (i.e. by oral administration).
AREAS COVERED: This review reports on compounds currently under development for 
the oral treatment of acute migraine attacks, focusing on 
Calcitonin-Gene-Related-Peptide receptor antagonists, specifically ubrogepant 
and rimegepant. This article is based on literature obtained from PubMed and 
publicly available clinical trial data.
EXPERT OPINION: Both reviewed compounds meet the need for rapid and effective 
pain control, combined with the control of associated bothersome symptoms while 
also lacking significant adverse events and safety concerns. Though further 
studies should assess the profile of these compounds comparatively with existing 
and available treatments (namely triptans), the currently available data points 
to these new therapies as being very promising new symptomatic oral treatments 
of migraines.